Amyloid precursor protein and endosomal-lysosomal dysfunction in Alzheimer's disease: inseparable partners in a multifactorial disease
Open accessThe DOI matches its Crossref record; 216 of the 218 references it cites were found in a registry or an index.
Abstract
Abnormalities of the endosomal–lysosomal network (ELN) are a signature feature of Alzheimer's disease (AD). These include the earliest known cytopathology that is specific to AD and that affects endosomes and induces the progressive failure of lysosomes, each of which are directly linked by distinct mechanisms to neurodegeneration. The origins of ELN dysfunction and β‐amyloidogenesis closely overlap, which reflects their common genetic basis, the established early involvement of endosomes and lysosomes in amyloid precursor protein (APP) processing and clearance, and the pathologic effect of certain APP metabolites on ELN functions. Genes that promote β‐amyloidogenesis in AD (APP, PSEN1/2, and APOE4) have primary effects on ELN function. The importance of primary ELN dysfunction to pathogenesis is underscored by the mutations in more than 35 ELN‐related genes that, thus far, are known to cause familial neurodegenerative diseases even though different pathogenic proteins may be involved. In this article, I discuss growing evidence that implicates AD gene–driven ELN disruptions as not only the antecedent pathobiology that underlies β‐amyloidogenesis but also as the essential partner with APP and its metabolites that drive the development of AD, including tauopathy, synaptic dysfunction, and neurodegeneration. The striking amelioration of diverse deficits in animal AD models by remediating ELN dysfunction further supports a need to integrate APP and ELN relationships, including the role of amyloid‐β, into a broader conceptual framework of how AD arises, progresses, and may be effectively therapeutically targeted.—Nixon, R. A. Amyloid precursor protein and endosomal–lysosomal dysfunction in Alzheimer's disease: inseparable partners in a multifactorial disease. FASEB J. 31, 2729–2743 (2017). www.fasebj.org
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“In summary, oxidative and/or nitrosative damage to multiple proteins, including synaptic proteins is very likely to contribute to the memory problems and other cognitive deficits, reduced ATP availability in neurons, and decreased clearance of abnormal proteins34, creating a “perfect storm” (or sTORm perhaps!) of detrimental cognitive effects in AD9,34,35,41,42.”
From Oxidative stress, dysfunctional glucose metabolism and Alzheimer disease (2019) · cites this paper as [42]
In the citing paper
“In addition to mTOR activation, insulin resistance can also result in neuronal glucose deficiency, with consequent decreased glucose metabolism, impaired ATP production, and dysfunction and/or death7,42”
From Oxidative stress, dysfunctional glucose metabolism and Alzheimer disease (2019) · cites this paper as [42]
In the citing paper
“Activated mTORC1 is intimately involved in regulation of protein synthesis, autophagy, mitochondrial function, lipogenesis, ketogenesis, and insulin signaling, and is crucially linked to glucose metabolism, where it becomes activated by growth factors, amino acids, and high cellular energy status41,42 (Fig 2).”
From Oxidative stress, dysfunctional glucose metabolism and Alzheimer disease (2019) · cites this paper as [42]
In the citing paper
“These oxidatively modified, and likely dysfunctional, proteins include ones associated with altered glucose metabolism, mTOR signaling (including inhibited autophagy and increased insulin resistance), and the proteostasis network42,61,62,65,66.”
From Oxidative stress, dysfunctional glucose metabolism and Alzheimer disease (2019) · cites this paper as [42]
In the citing paper
“This significant mediator of neuronal death is present in the early stages of AD, and evidence of impaired autophagy is also found in aMCI brain and PCAD brains41–43.”
From Oxidative stress, dysfunctional glucose metabolism and Alzheimer disease (2019) · cites this paper as [42]
19 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
2 retracted
RETRACTED ARTICLE: APP binds DR6 to trigger axon pruning and neuron death via distinct caspases
Nikolaev, A., McLaughlin, T., O’Leary, D. D. M., & Tessier-Lavigne, M. (2009) · Nature · doi:10.1038/nature07767 · Cited by 992
RetractedIntegrative genomics identifies APOE ε4 effectors in Alzheimer's disease
Rhinn, H., Fujita, R., Qiang, L., Cheng, R., Lee, J. H., & Abeliovich, A. (2013) · Nature · doi:10.1038/nature12415 · Cited by 171
RetractedRepertoires of Autophagy in the Pathogenesis of Ocular Diseases
Li, Y.-J., Jiang, Q., Cao, G.-F., Yao, J., & Yan, B. (2015) · Cellular Physiology and Biochemistry · doi:10.1159/000373980 · Cited by 16,304
Cui, C., Cui, J., Jin, F., Cui, Y., Li, R., Jiang, X., Tian, Y., Wang, K., Jiang, P., & Gao, J. (2017) · Cellular Physiology and Biochemistry · doi:10.1159/000479571 · Cited by 5,203
The role of autophagy in neurodegenerative disease
Nixon, R. A. (2013) · Nature Medicine · doi:10.1038/nm.3232 · Cited by 2,059
Self-citationNelson, P. T., Alafuzoff, I., Bigio, E. H., Bouras, C., Braak, H., Cairns, N. J., Castellani, R. J., Crain, B. J., Davies, P., Tredici, K. D., et al. (2012) · Journal of Neuropathology & Experimental Neurology · doi:10.1097/nen.0b013e31825018f7 · Cited by 2,050
CNS synaptogenesis promoted by glia-derived cholesterol
Mauch, D. H., Nägler, K., Schumacher, S., Göritz, C., Müller, E.-C., Otto, A., & Pfrieger, F. W. (2001) · Science · doi:10.1126/science.294.5545.1354 · Cited by 1,711 · cited 1×
“Of particular relevance to AD, lipoprotein receptors mediate glia-derived cholesterol transport within the CNS, which is essential to form and maintain synapses (108).”
BackgroundExtensive Involvement of Autophagy in Alzheimer Disease: An Immuno-Electron Microscopy Study
Nixon, R. A., Wegiel, J., Kumar, A., Yu, W. H., Peterhoff, C., Cataldo, A., & Cuervo, A. M. (2005) · Journal of Neuropathology & Experimental Neurology · doi:10.1093/jnen/64.2.113 · Cited by 1,588
Self-citationCellular prion protein mediates impairment of synaptic plasticity by amyloid-β oligomers
Laurén, J., Gimbel, D. A., Nygaard, H. B., Gilbert, J. W., & Strittmatter, S. M. (2009) · Nature · doi:10.1038/nature07761 · Cited by 1,560
Lysosomal membrane permeabilization in cell death
Boya, P., & Kroemer, G. (2008) · Oncogene · doi:10.1038/onc.2008.310 · Cited by 1,426
Research works printed but not linked: 1
- 10.1111/j.1365-2990.2010.01062.x · doi:10.1111/j.1365-2990.2010.01062.x · Paper page
Cited by
Knopman, D. S., Amieva, H., Petersen, R. C., Chételat, G., Holtzman, D. M., Hyman, B. T., Nixon, R. A., & Jones, D. T. (2021) · Nature Reviews Disease Primers · doi:10.1038/s41572-021-00269-y · Cited by 2,606
Self-citationOxidative stress, dysfunctional glucose metabolism and Alzheimer disease
Butterfield, D. A., & Halliwell, B. (2019) · Nature Reviews Neuroscience · doi:10.1038/s41583-019-0132-6 · Cited by 1,954
The Amyloid-β Pathway in Alzheimer’s Disease
Hampel, H., Hardy, J., Blennow, K., Chen, C., Perry, G., Kim, S. H., Villemagne, V. L., Aisen, P., Vendruscolo, M., Iwatsubo, T., et al. (2021) · Molecular Psychiatry · doi:10.1038/s41380-021-01249-0 · Cited by 1,952
“Alternatively, APP can enter the lysosomal pathway and undergo proteolytic degradation [105].”
BackgroundInfluentialLysosomes as dynamic regulators of cell and organismal homeostasis
Ballabio, A., & Bonifacino, J. S. (2020) · Nature Reviews Molecular Cell Biology · doi:10.1038/s41580-019-0185-4 · Cited by 1,469
Mizushima, N., & Levine, B. (2020) · New England Journal of Medicine · doi:10.1056/nejmra2022774 · Cited by 1,140
The lysosome as a cellular centre for signalling, metabolism and quality control
Lawrence, R. E., & Zoncu, R. (2019) · Nature Cell Biology · doi:10.1038/s41556-018-0244-7 · Cited by 920
Alzheimer's Disease: Treatment Strategies and Their Limitations.
Passeri, E., Elkhoury, K., Morsink, M., Broersen, K., Linder, M., Tamayol, A., Malaplate, C., Yen, F. T., & Arab-Tehrany, E. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms232213954 · Cited by 689
“Other factors, including abnormal lipid and glucose metabolism, neuroinflammation, cerebrovascular abnormalities [53], and endosomal pathway blockade [54], can also contribute to AD pathology in the brain [55].”
BackgroundMechanisms of autophagy–lysosome dysfunction in neurodegenerative diseases
Nixon, R. A., & Rubinsztein, D. C. (2024) · Nature Reviews Molecular Cell Biology · doi:10.1038/s41580-024-00757-5 · Cited by 435
“Ensuing free radical-mediated and proteotoxic damage to lysosomal membranes promotes the early autophagic–lysosomal death of affected neurons containing amyloid-β aggregates and their transformation into extracellular senile (‘amyloid-β’) plaques 131,132,134–136 (Fig.”
Self-citationBACE1 inhibitors: Current status and future directions in treating Alzheimer's disease
Moussa‐Pacha, N. M., Abdin, S. M., Omar, H. A., Alniss, H., & Al‐Tel, T. H. (2020) · Medicinal Research Reviews · doi:10.1002/med.21622 · Cited by 274
“GSK‐3 is a kinase that keeps glycogen synthase inactive via phosphorylation, whereas insulin tends to activate glycogen synthetase by dephosphorylation on the same sites.153 Therefore, in that manner insulin can act to block GSK‐3 thereby tackling AD.”
BackgroundInfluentialChen, X.-Q., & Mobley, W. C. (2019) · Frontiers in Neuroscience · doi:10.3389/fnins.2019.00659 · Cited by 289
“The enlargement of early endosomes and dysregulation of their function, with subsequent disruption of the endosomal and lysosomal pathways (Nixon, 2017; Chen et al., 2018) could serve to both mediate and amplify local AβO-mediated events.”
BackgroundFernández-Calle, R., Konings, S. C., Frontiñán-Rubio, J., García-Revilla, J., Camprubí-Ferrer, L., Svensson, M., Martinson, I., Boza-Serrano, A., Venero, J. L., Nielsen, H. M., et al. (2022) · Molecular Neurodegeneration · doi:10.1186/s13024-022-00566-4 · Cited by 278
Autophagy, aging, and age-related neurodegeneration
Palmer, J. E., Wilson, N., Son, S. M., Obrocki, P., Wrobel, L., Rob, M., Takla, M., Korolchuk, V. I., & Rubinsztein, D. C. (2025) · Neuron · doi:10.1016/j.neuron.2024.09.015 · Cited by 241
“99 Altered calcium signaling in AD also impairs lysosomal acidification.”
BackgroundEmerging roles of ER stress in the etiology and pathogenesis of Alzheimer's disease
Gerakis, Y., & Hetz, C. (2018) · The FEBS Journal · doi:10.1111/febs.14332 · Cited by 226
“29 Nixon RA (2017) Amyloid precursor protein and endosomal-lysosomal dysfunction in Alzheimer’s disease: inseparable partners in a multifactorial disease.”
BackgroundInfluentialDewanjee, S., Chakraborty, P., Bhattacharya, H., Chacko, L., Singh, B., Chaudhary, A., Javvaji, K., Pradhan, S. R., Vallamkondu, J., Dey, A., et al. (2022) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2022.09.032 · Cited by 229
Lysosomal storage disorders – challenges, concepts and avenues for therapy: beyond rare diseases
Marques, A. R. A., & Saftig, P. (2019) · Journal of Cell Science · doi:10.1242/jcs.221739 · Cited by 224
“For example, the impaired degradative capacity of lysosomes, reduced autophagy flow, altered lipid composition and different subcellular localization of lysosomes in neurons are all examples of lysosomal dysfunctions in common neurodegenerative diseases, such as Alzheimer’s disease (Nixon, 2017), Parkinson’s disease (…”
BackgroundNew insights into extracellular vesicle biogenesis and function
Latifkar, A., Hur, Y. H., Sanchez, J. C., Cerione, R. A., & Antonyak, M. A. (2019) · Journal of Cell Science · doi:10.1242/jcs.222406 · Cited by 221
“…disease (AD) are characterized by the loss of SIRT1 expression (Kim et al., 2007; Min et al., 2010) and lysosomal impairment (Fraldi et al., 2016; Nixon, 2017), and neurons have also been shown to form exosomes that have been implicated in the spread of the disease (Howitt and Hill, 2016).”
BackgroundBeyond autophagy: LC3-associated phagocytosis and endocytosis
Peña-Martinez, C., Rickman, A. D., & Heckmann, B. L. (2022) · Science Advances · doi:10.1126/sciadv.abn1702 · Cited by 208
Microglial Phagocytosis: A Disease-Associated Process Emerging from Alzheimer’s Disease Genetics
Podleśny-Drabiniok, A., Marcora, E., & Goate, A. M. (2020) · Trends in Neurosciences · doi:10.1016/j.tins.2020.10.002 · Cited by 211
Amyloid clearance defect in ApoE4 astrocytes is reversed by epigenetic correction of endosomal pH
Prasad, H., & Rao, R. (2018) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1801612115 · Cited by 207
“Dysfunction in endolysosomal pH is an emerging theme in AD with clear potential for intervention to exploit the diseasemodifying effects of endosomal pH (19).”
BackgroundLiu, J., Li, H., Gong, T., Chen, W., Mao, S., Kong, Y., Yu, J., & Sun, J. (2020) · Journal of Agricultural and Food Chemistry · doi:10.1021/acs.jafc.0c02807 · Cited by 199
The Role of APOE and TREM2 in Alzheimer′s Disease—Current Understanding and Perspectives
Wolfe, C. M., Fitz, N. F., Nam, K. N., Lefterov, I., & Koldamova, R. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms20010081 · Cited by 187
Multifactorial Hypothesis and Multi-Targets for Alzheimer’s Disease
Gong, C.-X., Liu, F., & Iqbal, K. (2018) · Journal of Alzheimer's Disease · doi:10.3233/jad-179921 · Cited by 182
Diagnostic and therapeutic potential of exosomes in Alzheimer’s disease
Soares Martins, T., Trindade, D., Vaz, M., Campelo, I., Almeida, M., Trigo, G., da Cruz e Silva, O. A. B., & Henriques, A. G. (2021) · Journal of Neurochemistry · doi:10.1111/jnc.15112 · Cited by 174
“Lysosomal dysfunction is another AD feature related to APP impaired metabolism that probably precedes AD pathogenesis (Nixon, 2017).”
BackgroundColacurcio, D. J., Pensalfini, A., Jiang, Y., & Nixon, R. A. (2018) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2017.10.001 · Cited by 167
“In AD, defects in endocytosis and autophagy have emerged as key drivers of accumulation of cellular waste products, progressive neuronal dysfunction, and neurodegeneration; which we have described previously [133].”
BackgroundSelf-citationLysosomal Dysfunction in Down Syndrome Is APP-Dependent and Mediated by APP-βCTF (C99)
Jiang, Y., Sato, Y., Im, E., Berg, M., Bordi, M., Darji, S., Kumar, A., Mohan, P. S., Bandyopadhyay, U., Diaz, A., et al. (2019) · The Journal of Neuroscience · doi:10.1523/jneurosci.0578-19.2019 · Cited by 166
“…early APP- CTFmediated lysosomal deficits may catalyze progressive lysosomal corruption via the buildup of intraneuronal A and other oxidized substrates that further impede substrate hydrolysis, damage lysosomal membranes, and catalyze neurodegeneration in AD (Nixon, 2017; Colacurcio et al., 2018).”
BackgroundInfluentialSelf-citationHuman Microglia Show Unique Transcriptional Changes in Alzheimer's Disease
Prater, K. E., Green, K. J., Mamde, S., Sun, W., Cochoit, A., Smith, C. L., Chiou, K. L., Heath, L., Rose, S. E., Wiley, J., et al. (2023) · Nature Aging · doi:10.1038/s43587-023-00424-y · Cited by 164
Hung, C. O. Y., & Livesey, F. J. (2018) · Cell Reports · doi:10.1016/j.celrep.2018.11.095 · Cited by 159
“Endosomes are highly active processing sites for APP, and accumulation of enlarged early endosomes and lysosomes in neurons has been observed in post-mortem brain samples of patients with sporadic AD and some forms of familial AD (Cataldo et al., 2000, 2001; Colacurcio et al., 2018; Nixon, 2017).”
BackgroundResultInfluentialMembrane trafficking in health and disease
Yarwood, R., Hellicar, J., Woodman, P. G., & Lowe, M. (2020) · Disease Models & Mechanisms · doi:10.1242/dmm.043448 · Cited by 169
“…to Aβ (which itself can disrupt endocytic traffic), the uptake of toxic Aβ aggregates from the cell exterior, the production of synaptic vesicles or abundance of post-synaptic receptors, or by altering lysosome homeostasis and autophagy pathways that are important for cell viability (Nixon, 2017).”
BackgroundThe aging lysosome: An essential catalyst for late-onset neurodegenerative diseases
Nixon, R. A. (2020) · Biochimica et Biophysica Acta (BBA) - Proteins and Proteomics · doi:10.1016/j.bbapap.2020.140443 · Cited by 149
“These observations are reminiscent of the delayed synergy among AD-related pathogenic proteins and the striking reduction in v-ATPase function caused by Presenilin-1 mutations (Lee et al., 2010; Nixon, 2017).”
BackgroundSelf-citationThe endosomal-lysosomal pathway is dysregulated by APOE4 expression in vivo
Nuriel, T., Peng, K. Y., Ashok, A., Dillman, A. A., Figueroa, H. Y., Apuzzo, J., Ambat, J., Levy, E., Cookson, M. R., Mathews, P. M., et al. (2017) · Frontiers in Neuroscience · doi:10.3389/fnins.2017.00702 · Cited by 140
“…pathway in both the production of Aβ (see review by Thinakaran and Koo, 2008) and the clearance of pathogenic proteins (see review by Nixon, 2017), we believe that APOE4-associated endosomal–lysosomal system dysregulation may be an early instigator of AD pathogenesis among APOE4…”
BackgroundPolanco, J. C., Hand, G. R., Briner, A., Li, C., & Götz, J. (2021) · Acta Neuropathologica · doi:10.1007/s00401-020-02254-3 · Cited by 131
Fedeli, C., Filadi, R., Rossi, A., Mammucari, C., & Pizzo, P. (2019) · Autophagy · doi:10.1080/15548627.2019.1596489 · Cited by 127
“formation of both protein aggregates [1,3].”
Pensalfini, A., Kim, S., Subbanna, S., Bleiwas, C., Goulbourne, C. N., Stavrides, P. H., Jiang, Y., Lee, J.-H., Darji, S., Pawlik, M., et al. (2020) · Cell Reports · doi:10.1016/j.celrep.2020.108420 · Cited by 125
Self-citationPhosphoinositides: Regulators of Nervous System Function in Health and Disease
Raghu, P., Joseph, A., Krishnan, H., Singh, P., & Saha, S. (2019) · Frontiers in Molecular Neuroscience · doi:10.3389/fnmol.2019.00208 · Cited by 121
“Finally, PI3P has been found to be selectively deficient in the brains of human patients with Alzheimer’s disease (Morel et al., 2013) and mouse models of Alzheimer’s disease with associated defects in endosomal-lysosomal network [reviewed in Nixon (2017)].”
BackgroundMitochondria, lysosomes, and dysfunction: their meaning in neurodegeneration
Audano, M., Schneider, A., & Mitro, N. (2018) · Journal of Neurochemistry · doi:10.1111/jnc.14471 · Cited by 122
Lo, C. H., & Zeng, J. (2023) · Translational Neurodegeneration · doi:10.1186/s40035-023-00362-0 · Cited by 117
The involvement of stress granules in aging and aging‐associated diseases
Cao, X., Jin, X., & Liu, B. (2020) · Aging Cell · doi:10.1111/acel.13136 · Cited by 121
“…activity and lysosomes decline in an age-dependent manner in muscles, heart, liver, intestine, pharynx, and neurons (Figure 1e; Chang, Kumsta, Hellman, Adams, & Hansen, 2017; Cuervo & Dice, 2000; Del Roso et al., 2003; Donati et al., 2001; Jiao & Demontis, 2017; Nixon, 2017; Yan & Finkel, 2017).”
BackgroundAre N- and C-terminally truncated Aβ species key pathological triggers in Alzheimer's disease?
Dunys, J., Valverde, A., & Checler, F. (2018) · Journal of Biological Chemistry · doi:10.1074/jbc.r118.003999 · Cited by 114
Autophagy–lysosomal-associated neuronal death in neurodegenerative disease
Nixon, R. A. (2024) · Acta Neuropathologica · doi:10.1007/s00401-024-02799-7 · Cited by 133
“APP-βCTF binds selectively to the V0a1 subunit and inhibits this association [94], thus linking its elevation in the lysosomes of AD neurons to the early decline in acidification [102, 130] and extreme autolysosomal and lysosomal pathology [94, 102, 124, 126, 130, 163].”
Self-citationApolipoprotein E4 genotype compromises brain exosome production
Peng, K. Y., Pérez-González, R., Alldred, M. J., Goulbourne, C. N., Morales-Corraliza, J., Saito, M., Saito, M., Ginsberg, S. D., Mathews, P. M., & Levy, E. (2019) · Brain · doi:10.1093/brain/awy289 · Cited by 109
“…endosomal-lysosomal and exosomal pathways in APOE4 carriers during ageing may not only disturb essential homeostatic and catabolic cellular processes, but may also contribute to neuronal vulnerability and the risk of developing neurodegenerative disorders such as Alzheimer’s disease (Nixon, 2017).”
Ferguson, S. M. (2019) · Neuroscience Letters · doi:10.1016/j.neulet.2018.04.005 · Cited by 105
Hung, C., Tuck, E., Stubbs, V., van der Lee, S. J., Aalfs, C., van Spaendonk, R., Scheltens, P., Hardy, J., Holstege, H., & Livesey, F. J. (2021) · Cell Reports · doi:10.1016/j.celrep.2021.109259 · Cited by 98
“…accumulation of APP protein fragments generated from the amyloidogenic pathway within endosomal compartments disrupts endolysosomal function and autophagy (Colacurcio et al., 2018; Jiang et al., 2016, 2019; Kwart et al., 2019; Lauritzen et al., 2016, 2019; Nixon, 2007, 2017; Nixon et al., 2005).”
BackgroundButterfield, D. A. (2020) · Ageing Research Reviews · doi:10.1016/j.arr.2020.101049 · Cited by 93
“…and MCI are characterized by decreased autophagy and other components of the proteostasis network and by insulin resistance, both associated with elevated lipid peroxidation and activation of the mechanistic target of rapamycin (Di Domenico et al., 2017b; Tramutola et al., 2015; Nixon, 2017).”
BackgroundProteostasis and lysosomal repair deficits in transdifferentiated neurons of Alzheimer’s disease
Chou, C.-C., Vest, R., Prado, M. A., Wilson-Grady, J., Paulo, J. A., Shibuya, Y., Moran-Losada, P., Lee, T.-T., Luo, J., Gygi, S. P., et al. (2025) · Nature Cell Biology · doi:10.1038/s41556-025-01623-y · Cited by 94
Down syndrome and Alzheimer's disease: common molecular traits beyond the amyloid precursor protein
Gómez, W., Morales, R., Maracaja‐Coutinho, V., Parra, V., & Nassif, M. (2020) · Aging · doi:10.18632/aging.102677 · Cited by 102
“Confirming these results, endocytic abnormalities were reversed by reducing the expression of APP or BACE1 in APP-transgenic mouse models of AD (TgAPP mice) [62].”
BackgroundMonaco, A., & Fraldi, A. (2020) · Frontiers in Molecular Neuroscience · doi:10.3389/fnmol.2020.00037 · Cited by 95
“…reported that the functionality of endo-lysosomal recycling trafficking is critical for determining the amyloidogenic cascade (Rajendran and Annaert, 2012; Das et al., 2013) and, therefore, any detrimental effect on the endo-lysosomal transport results in alterations of Aβ production (Nixon, 2017).”
BackgroundAlzheimer’s disease – the journey of a healthy brain into organ failure
Golde, T. E. (2022) · Molecular Neurodegeneration · doi:10.1186/s13024-022-00523-1 · Cited by 88
Expression of WIPI2B counteracts age-related decline in autophagosome biogenesis in neurons
Stavoe, A. K., Gopal, P. P., Gubas, A., Tooze, S. A., & Holzbaur, E. L. (2019) · eLife · doi:10.7554/elife.44219 · Cited by 82
Proteotoxicity and Neurodegenerative Diseases
Ruz, C., Alcantud, J. L., Montero, F. V., Durán, R., & Bandrés‐Ciga, S. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21165646 · Cited by 89
“This toxic effect would be mediated by a reduction in the electron transport chain enzymatic activities [186,187].”
BackgroundLambeth, T. R., Riggs, D. L., Talbert, L. E., Tang, J. Y., Coburn, E., Kang, A. S., Noll, J. M., Augello, C. J., Ford, B. D., & Julian, R. R. (2019) · ACS Central Science · doi:10.1021/acscentsci.9b00369 · Cited by 88
Preserving Lysosomal Function in the Aging Brain: Insights from Neurodegeneration
Peng, W., Minakaki, G., Nguyen, M., & Krainc, D. (2019) · Neurotherapeutics · doi:10.1007/s13311-019-00742-3 · Cited by 79
Lee, J.-H., Rao, M. V., Yang, D.-S., Stavrides, P., Im, E., Pensalfini, A., Huo, C., Sarkar, P., Yoshimori, T., & Nixon, R. A. (2019) · Autophagy · doi:10.1080/15548627.2018.1528812 · Cited by 82
“ALP [49] that both promote amyloidosis and global impairment of cellular clearance of damaged and toxic proteins.”
BackgroundSelf-citationThe role of Alzheimer's disease risk genes in endolysosomal pathways
Szabo, M. P., Mishra, S., Knupp, A., & Young, J. E. (2022) · Neurobiology of Disease · doi:10.1016/j.nbd.2021.105576 · Cited by 82
“Conversion of EEs to downstream endosomal compartments in the ELN occurs through endosomal maturation that involves a gradual acidification of the lumen(Huotari and Helenius, 2011).”
InfluentialIGF2 in memory, neurodevelopmental disorders, and neurodegenerative diseases
Alberini, C. M. (2023) · Trends in Neurosciences · doi:10.1016/j.tins.2023.03.007 · Cited by 89
Loeffler, D. A. (2023) · Journal of Alzheimer's Disease Reports · doi:10.3233/adr-230025 · Cited by 79
“It is degraded via the endosomallysosomal system [16], the ubiquitin-proteasome system [17], and autophagy [18]; A efflux from the brain is via the blood-brain barrier (BBB) [19], the blood cerebrospinal fluid (CSF) barrier [20], glymphatic (paravascular) drainage [21], and perivascular drainage [22].”
BackgroundIm, E., Jiang, Y., Stavrides, P. H., Darji, S., Erdjument-Bromage, H., Neubert, T. A., Choi, J. Y., Wegiel, J., Lee, J.-H., & Nixon, R. A. (2023) · Science Advances · doi:10.1126/sciadv.adg1925 · Cited by 80
Self-citationKaur, G., Tan, L. X., Rathnasamy, G., La Cunza, N., Germer, C. J., Toops, K. A., Fernandes, M., Blenkinsop, T. A., & Lakkaraju, A. (2018) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1805039115 · Cited by 79
“These studies have implications beyond the retina: ceramide is increased in AD patient brains (28), raising the intriguing possibility of synergism between ceramide and the recently described Rab5 hyperactivation mechanism (29) to promote EE enlargement in neurons.”
BackgroundCao, J., Zhong, M. B., Toro, C. A., Zhang, L., & Cai, D. (2019) · Neuroscience Letters · doi:10.1016/j.neulet.2019.03.016 · Cited by 79
“In turn, excessive βCTFs and Aβ also increase active forms of Rab5, and lead to enlarged endosomes and accelerated amyloidogenic processing of APP [38].”
BackgroundSharoar, M. G., Palko, S., Ge, Y., Saido, T. C., & Yan, R. (2021) · Molecular Neurodegeneration · doi:10.1186/s13024-021-00464-1 · Cited by 78
Exosome Production Is Key to Neuronal Endosomal Pathway Integrity in Neurodegenerative Diseases
Mathews, P. M., & Levy, E. (2019) · Frontiers in Neuroscience · doi:10.3389/fnins.2019.01347 · Cited by 75
“In vivo, continuous intracerebral infusion of exogenous neuroblastoma-produced EVs apparently trapped and targeted for microglial phagocytosis sufficient Aβ in the brain of APP overexpressing transgenic mice to reduce Aβ levels, amyloid deposition, and synaptotoxicity in the hippocampus (Yuyama et al., 2014).”
BackgroundInfluentialHou, X., Watzlawik, J. O., Cook, C. N., Liu, C., Kang, S. S., Lin, W., Deture, M. A., Heckman, M. G., Diehl, N. N., Al‐Shaikh, F. S. H., et al. (2020) · Alzheimer s & Dementia · doi:10.1002/alz.12198 · Cited by 80
APOE2 orchestrated differences in transcriptomic and lipidomic profiles of postmortem AD brain
Lefterov, I., Wolfe, C. M., Fitz, N. F., Nam, K. N., Letronne, F., Biedrzycki, R. J., Kofler, J., Han, X., Wang, J., Schug, J., et al. (2019) · Alzheimer's Research & Therapy · doi:10.1186/s13195-019-0558-0 · Cited by 74
“During the course of AD, autophagy and macroautophagy have a range of effects—deleterious as well as protective, depending on the stage of the pathologic process [55, 56].”
BackgroundLauritzen, I., Pardossi-Piquard, R., Bourgeois, A., Bécot, A., & Checler, F. (2019) · Current Alzheimer Research · doi:10.2174/1567205016666190325092841 · Cited by 67
Liang, J., Wang, C., Zhang, H., Huang, J., Xie, J., & Chen, N. (2021) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2021.755665 · Cited by 75
“The injection of Beclin1 can reduce the accumulation of hyperphosphorylated Tau protein (Nixon, 2017).”
BackgroundLambert, E., Saha, O., Soares Landeira, B., Melo de Farias, A. R., Hermant, X., Carrier, A., Pelletier, A., Gadaut, J., Davoine, L., Dupont, C., et al. (2022) · Acta Neuropathologica Communications · doi:10.1186/s40478-021-01285-5 · Cited by 65
The amyloid precursor protein: a converging point in Alzheimer’s disease
Delport, A., & Hewer, R. (2022) · Molecular Neurobiology · doi:10.1007/s12035-022-02863-x · Cited by 67
“Abnormalities in the endosome–lysosome system are frequently-recorded early features of AD [50, 51].”
BackgroundJiang, Y., Alam, J. J., Gomperts, S. N., Maruff, P. T., Lemstra, A. W., Germann, U. A., Stavrides, P. H., Darji, S., Malampati, S., Peddy, J., et al. (2022) · Nature Communications · doi:10.1038/s41467-022-32944-3 · Cited by 72
“determined by Image J analysis [n = 4 mice per group; for number: F(3,12) = 7.”
MethodSelf-citationChen, X., Sawa, M., & Mobley, W. C. (2017) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2017.10.341 · Cited by 70
Decourt, B., D’Souza, G. X., Shi, J., Ritter, A., Suazo, J., & Sabbagh, M. N. (2022) · Aging and disease · doi:10.14336/ad.2021.0529 · Cited by 69
“BACE1 cleaves APP in the outer space near the plasma membrane and lysosomes [19] to release a large soluble extracellular fragment called sAPPβ.”
BackgroundAlzheimer’s disease and the autophagic-lysosomal system
Chung, K. M., Hernández, N., Sproul, A. A., & Yu, W. H. (2019) · Neuroscience Letters · doi:10.1016/j.neulet.2018.05.017 · Cited by 63
Rimal, S., Li, Y., Vartak, R. S., Geng, J., Tantray, I., Li, S., Huh, S., Vogel, H. S., Glabe, C. G., Grinberg, L. T., et al. (2021) · Acta Neuropathologica Communications · doi:10.1186/s40478-021-01268-6 · Cited by 65
Somogyi, A., Kirkham, E. D., Lloyd‐Evans, E., Winston, J., Allen, N. D., Mackrill, J. J., Anderson, K. E., Hawkins, P. T., Gardiner, S. E., Waller‐Evans, H., et al. (2023) · Journal of Cell Science · doi:10.1242/jcs.259875 · Cited by 68
“I do hope you find the comments of the reviewers helpful in allowing you to revise the manuscript for submission elsewhere, and many thanks for sending your work to Journal of Cell Science.”
Is γ-secretase a beneficial inactivating enzyme of the toxic APP C-terminal fragment C99?
Checler, F., Afram, E., Pardossi-Piquard, R., & Lauritzen, I. (2021) · Journal of Biological Chemistry · doi:10.1016/j.jbc.2021.100489 · Cited by 59
Reverse electron transfer is activated during aging and contributes to aging and age‐related disease
Rimal, S., Tantray, I., Li, Y., Khaket, T. P., Li, Y., Bhurtel, S., Li, W., Zeng, C., & Lu, B. (2023) · EMBO Reports · doi:10.15252/embr.202255548 · Cited by 64
“C99 induces proteostasis failure and endolysosomal defects (Rimal et al , 2021), which are regarded as cellular hallmarks of AD (Nixon, 2017).”
A New Hypothesis for Alzheimer’s Disease: The Lipid Invasion Model
Rudge, J. D. (2022) · Journal of Alzheimer's Disease Reports · doi:10.3233/adr-210299 · Cited by 58
“Certainly, this interpretation, that such AD pathology results from excessive cholesterol uptake from larger lipoproteins of plasma origin, fits in well with the evidence that excessive cholesterol stimulates amyloidogenic processing of A PP within early endosomes, given that cellular LDLcholesterol uptake is known to…”
BackgroundInfluentialThe Bis(monoacylglycero)-phosphate Hypothesis: From Lysosomal Function to Therapeutic Avenues
Medoh, U. N., & Abu-Remaileh, M. (2024) · Annual Review of Biochemistry · doi:10.1146/annurev-biochem-092823-113814 · Cited by 63
“Often overlooked, the deposition of lipid saccules in microglia is an additional pathological feature, and apolipoprotein E4 (APOE4), the strongest risk factor for AD, impairs myelination in oligodendrocytes due to cholesterol dyshomeostasis (83–85).”
Pharmacological modulation of autophagy for Alzheimer's disease therapy: Opportunities and obstacles
Deng, Z., Dong, Y., Zhou, X., Lu, J.-H., & Yue, Z. (2022) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2021.12.009 · Cited by 58
Alam, J. J., Blackburn, K., & Patrick, D. (2017) · PubMed · doi:10.14283/jpad.2017.41 · Cited by 57
Chen, X., Salehi, A., Pearn, M. L., Overk, C., Nguyen, P. D., Kleschevnikov, A. M., Maccecchini, M., & Mobley, W. C. (2021) · Alzheimer's & Dementia · doi:10.1002/alz.12185 · Cited by 54
Singh, A., Upadhayay, S., & Mehan, S. (2021) · Neurotoxicity Research · doi:10.1007/s12640-021-00401-6 · Cited by 54
“Neuronal p38MAPK signaling alterations have been attributed to neurological dysfunctions such as AD (Nixon 2017), PD (Alam and Scheper 2016), ALS (Malik et al.”
BackgroundLi, H., Zheng, T., Lian, F., Xu, T., Yin, W., & Jiang, Y. (2021) · Nutrition · doi:10.1016/j.nut.2021.111473 · Cited by 57
Impact of increased APP gene dose in Down syndrome and the Dp16 mouse model
Sawa, M., Overk, C., Becker, A., Derse, D., Albay, R., Weldy, K., Salehi, A., Beach, T. G., Doran, E., Head, E., et al. (2022) · Alzheimer's & Dementia · doi:10.1002/alz.12463 · Cited by 54
Cholesterol determines the cytosolic entry and seeded aggregation of tau
Tuck, B. J., Miller, L. V. C., Katsinelos, T., Smith, A. E., Wilson, E. L., Keeling, S., Cheng, S., Vaysburd, M. J., Knox, C., Tredgett, L., et al. (2022) · Cell Reports · doi:10.1016/j.celrep.2022.110776 · Cited by 57
“This is consistent with previous studies that have reported leaky vesicles upon induction of endolysosomal perturbation (Calafate et al., 2016; Nixon, 2017).”
ResultA genetically modified minipig model for Alzheimer’s disease with SORL1 haploinsufficiency
Andersen, O. M., Bøgh, N., Landau, A. M., Pløen, G. G., Jensen, A. M. G., Monti, G., Ulhøi, B. P., Nyengaard, J. R., Jacobsen, K. R., Jørgensen, M. M., et al. (2022) · Cell Reports Medicine · doi:10.1016/j.xcrm.2022.100740 · Cited by 48
“Because of their similarities to humans in terms of genetics, anatomy, physiology, and biochemistry, minipigs are valuable animal models for drug testing and are being increasingly employed as non-rodent models for toxicity testing and safety pharmacology,67,68 adding to the utility of our Göttingen minipig SORL1 het…”
BackgroundInfluentialPérez‐González, R., Kim, Y., Miller, C., Pacheco‐Quinto, J., Eckman, E. A., & Levy, E. (2020) · The FASEB Journal · doi:10.1096/fj.202000823r · Cited by 52
García-Aguilar, A., Palomino, O. M., Benito, M., & Guillén, C. (2021) · Antioxidants · doi:10.3390/antiox10020142 · Cited by 57
“In addition, it has been shown that Aβ is able to accumulate lysosomes inside itself, thus altering their membrane permeability [130].”
BackgroundGraphene oxide enhances β-amyloid clearance by inducing autophagy of microglia and neurons
Li, X., Li, K., Chu, F., Huang, J., & Yang, Z. (2020) · Chemico-Biological Interactions · doi:10.1016/j.cbi.2020.109126 · Cited by 51
The Role of Cysteine Protease Cathepsins B, H, C, and X/Z in Neurodegenerative Diseases and Cancer
Stoka, V., Vasiljeva, O. S., Nakanishi, H., & Türk, V. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms242115613 · Cited by 57
“Recently, Nixon proposed a multifactorial disease model wherein β -amyloidogenesis and the endolysosomal network have been identified as essential for the cause and progression of AD [151].”
Background(2020) · International Review of Neurobiology · doi:10.1016/bs.irn.2020.03.018 · Cited by 50
Stanciu, G. D., Rusu, R. N., Bild, V., Filipiuc, L. E., Tamba, B.-I., & Ababei, D. C. (2021) · Biomedicines · doi:10.3390/biomedicines9050576 · Cited by 47
“They provide a basis for therapeutic approaches to restore AD-related metabolic, mitochondrial and endo-lysosomal dysfunctions; changes that occur early in the progression of the disease in relation to tau and Aβ deposition, which means that they are viable factors of AD development [34,35].”
BackgroundSun, H., Leng, H., Liu, J., Roy, G., Yan, J., & Zhang, L. (2019) · Sensors and Actuators B Chemical · doi:10.1016/j.snb.2019.127509 · Cited by 47
Zhao, Y., Long, Z., Ding, Y. L., Jiang, T., Liu, J., Li, Y., Liu, Y., Peng, X., Wang, K., Feng, M. H., et al. (2020) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2020.00047 · Cited by 50
“In AD, dysfunctional autophagic flux was characterized as accumulating levels of APs in dystrophic neurites, whereas APP, Aβ peptides, β-site APP cleaving enzyme (BACE1) protein, damaged mitochondria and Golgi fragments are rich and cannot be cleared away by endosomal–lysosomal degradation process (Yu et al., 2005; Jo…”
InfluentialFrom beta amyloid to altered proteostasis in Alzheimer’s disease
Bruni, A. C., Bernardi, L., & Gabelli, C. (2020) · Ageing Research Reviews · doi:10.1016/j.arr.2020.101126 · Cited by 53
Lanzillotta, C., Tramutola, A., Di Giacomo, G., Marini, F., Butterfield, D. A., Di Domenico, F., Perluigi, M., & Barone, E. (2021) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2021.01.042 · Cited by 47
Moss, D. E., & Perez, R. G. (2021) · Current Alzheimer Research · doi:10.2174/1567205018666211215150547 · Cited by 48
“The problem of finding an effective disease-modifying treatment may be due to increasing evidence that there are different subtypes of AD [6,7] that begin many years before the onset of dementia as shown by varying biomarkers including amyloidosis [8,9], tauopathy [7,10,11], inflammation [12,13], and AD-associated los…”
BackgroundChen, Y., Jin, H., Chen, J., Li, J., Găman, M., & Zou, Z. (2025) · Cell Death Discovery · doi:10.1038/s41420-025-02600-y · Cited by 64
“(4) Endosomal Traf fi cking Abnormalities: ApoE4 promotes APP internalization and colocalizes APP and BACE1 in early endosomes, delaying endosomal-lysosomal traf fi cking and APP processing, thus promoting A β generation [18 – 20].”
Alzheimer’s Disease Model System Using Drosophila
Tsuda, L., & Lim, Y. (2018) · Advances in experimental medicine and biology · doi:10.1007/978-981-13-0529-0_3 · Cited by 50
Pacheco-Quinto, J., Clausen, D., Pérez-González, R., Peng, H., Meszaros, A., Eckman, C. B., Levy, E., & Eckman, E. A. (2019) · The FASEB Journal · doi:10.1096/fj.201801319r · Cited by 45
NHE6 depletion corrects ApoE4-mediated synaptic impairments and reduces amyloid plaque load
Pohlkamp, T., Xian, X., Wong, C. H., Durakoglugil, M. S., Werthmann, G. C., Saido, T. C., Evers, B. M., White, C. L., Connor, J., Hammer, R. E., et al. (2021) · eLife · doi:10.7554/elife.72034 · Cited by 46
Regulatory role of cathepsin L in induction of nuclear laminopathy in Alzheimer’s disease
Islam, M. R., Nagakannan, P., Shcholok, T., Contu, F., Mai, S., Albensi, B. C., Bigio, M. R. D., Wang, J., Sharoar, M. G., Yan, R., et al. (2021) · Aging Cell · doi:10.1111/acel.13531 · Cited by 46
“The involvement of endo- lysosomal dysfunction and lysosomal enzymes in AD- associated neuronal cell death is well documented (Hung & Livesey, 2018; Nixon, 2013, 2017).”
Background
Metadata
- Authors
- Nixon, R. A.
- Affiliations
- Nathan Kline Institute for Psychiatric Research (US)
- Corresponding author
- Nixon, Ralph A.
- ORCID
- Nixon, Ralph A.
- Venue
- The FASEB Journal
- Publisher
- Wiley
- Published
- 2017-06-14
- Volume
- 31
- Issue
- 7
- Pages
- 2729-2743
- ISSN
- 0892-6638 (ISSN-L)
- 1530-6860
- PMC
- PMC6137496
- OpenAlex
- W2728546490
- Cited by
- 400
- References
- 218
- Citations by year
- 2026: 39 · 2025: 55 · 2024: 44 · 2023: 36 · 2022: 50 · 2021: 55 · 2020: 55 · 2019: 34 · 2018: 25 · 2017: 7
- FWCI
- 4.06
- Type
- journal article
- Language
- en
- Open access
- green
- europepmc.org
- Locations
- The FASEB Journal (publishedVersion)
- Europe PMC (PubMed Central) (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- HAL (submittedVersion, other-oa)
- Funders
- National Institutes of Health
- National Institute on Aging
- Topics
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cell Biology › Cellular transport and secretion
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cell Biology › Autophagy in Disease and Therapy
- Keywords
- Alzheimer's disease, amyloid precursor protein, lysosomal dysfunction, endosomes, APP processing, presenilin 1, presenilin 2, APOE ε4, tauopathy, synaptic dysfunction, neurodegeneration, familial neurodegenerative disease, animal models of Alzheimer's disease, therapeutic target
- MeSH terms
- Alzheimer Disease, Gene Expression Regulation, Humans, Lysosomes, Endosomes, Amyloid beta-Protein Precursor
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.